Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) traded up 0.6% during mid-day trading on Friday . The stock traded as high as $5.55 and last traded at $5.40. 110,887 shares were traded during mid-day trading, an increase of 91% from the average session volume of 58,182 shares. The stock had previously closed at $5.37.
Analyst Ratings Changes
Several analysts have commented on DMAC shares. Oppenheimer reaffirmed an "outperform" rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, August 16th. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.
Read Our Latest Stock Analysis on DMAC
DiaMedica Therapeutics Trading Up 0.6 %
The business's fifty day moving average price is $4.51 and its 200-day moving average price is $3.76.
Hedge Funds Weigh In On DiaMedica Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in DiaMedica Therapeutics in the 3rd quarter worth approximately $40,000. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter worth approximately $87,000. Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at $185,000. Geode Capital Management LLC grew its holdings in shares of DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock valued at $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company's stock worth $2,807,000 after purchasing an additional 211,351 shares during the period. 10.12% of the stock is currently owned by hedge funds and other institutional investors.
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Articles
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
